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Abstract Over the period 1987–1991 an inter-disciplinary
five-country group developed the EuroQol instrument, a
five-dimensional three-level generic measure subsequently
termed the ‘EQ-5D’. It was designed to measure and value
health status. The salient features of its development and its
consolidation and expansion are discussed. Initial expan-
sion came, in particular, in the form of new language
versions. Their development raised translation and
semantic issues, experience with which helped feed into the
design of two further instruments, the EQ-5D-5L and the
youth version EQ-5D-Y. The expanded usage across clin-
ical programmes, disease and condition areas, population
surveys, patient-reported outcomes, and value sets is out-
lined. Valuation has been of continued relevance for the
Group as this has allowed its instruments to be utilised as
part of the economic appraisal of health programmes and
their incorporation into health technology assessments. The
future of the Group is considered in the context of: (1) its
scientific strategy, (2) changes in the external environment
affecting the demand for EQ-5D, and (3) a variety of issues
it is facing in the context of the design of the instrument, its
use in health technology assessment, and potential new
uses for EQ-5D outside of clinical trials and technology
appraisal.
Key Points for Decision Makers
The EQ-5D portfolio of health status instruments,
EQ-5D-3L, EQ-5D-5L and EQ-5D-Y, is the product
of nearly 30 years of development and adaptation.
These instruments have been applied in a variety of
health sector settings, in patient-reported outcome
exercises, in population health studies, and in health
technology assessment.
A wide-ranging programme of research studies is in
process to adapt and further develop the EuroQol
portfolio.
1 Introduction
The EQ-5D is a well-known and widely used health status
instrument. It was developed by the EuroQol Group in the
1980s to provide a concise, generic instrument that could
be used to measure, compare and value health status across
disease areas.
The initial Group participants were from a variety of
professional backgrounds with a common interest in the
measurement of health status and in the outcomes of
healthcare programmes. The development of the instru-
ment was motivated in part by health economics consid-
erations, i.e. to create a way of measuring health status to
inform resource allocation decisions by enabling the
application of cost-effectiveness analysis (CEA) to health
care. Aiming at valuing health states gave the potential for
the instrument to estimate quality-adjusted life-years
(QALYs) for use in CEA.
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Valuation, however, was not the sole consideration of
the Group, and this has been confirmed by the incorpora-
tion of EQ-5D into clinical trials, observational studies,
population health surveys and, more recently, into routine
outcome measurement via Patient Reported Outcome
(PRO) measures in the healthcare sector.
The aims of this paper are to: (1) describe the prove-
nance and development of the EQ-5D by the EuroQol
Group, and to highlight the factors that contributed to its
widespread use as a generic instrument; (2) outline the
current state of play with respect to the use and application
of EQ-5D and further development of the suite of EQ-5D
instruments, and (3) consider the future of the EQ-5D,
including the research directions signalled by the Group,
and the challenges that might shape its future use and
development.
2 A Brief History of the EQ-5D
Detailed histories of the EuroQol Group and its develop-
ment of the EQ-5D are available elsewhere [1–3]. In this
paper the focus is on the following questions: Why was the
EQ-5D initially developed? How did its use and applica-
tion evolve? How will the EuroQol Group proceed?
2.1 The Provenance of the EQ-5D
The EuroQol Group started its journey in 1987: 14 people
met to exchange ideas about how to approach the devel-
opment of a health status measurement instrument. One of
the motivations for doing so was to assist healthcare
decision-makers to make resource allocation decisions
informed by evidence on the cost-effectiveness of alter-
native treatments.
From the outset the Group therefore sought a ‘common
core’ of basic information or key attributes to be collected
by all investigators in a standardised way. This came to be
crystallised in the following set of objectives: (1) To
develop a generic instrument to describe and value health-
related quality of life (HRQoL), providing both a
descriptive profile and an overall index. (2) It was to be a
standardised tool to facilitate the collection and pooling of
a common data set. (3) It was to be suitable for self-
completion and acceptable for use in postal surveys (at that
point, a common mode of data collection). These objec-
tives in turn led to a number of requirements for the
descriptive system: (1) dimensions should be relevant to
patients across the spectrum of health care and to members
of the general population. (2) It should be simple—using as
few dimensions as possible, with as few levels as possible
within each dimension. (3) It should be amenable to self-
completion in a range of settings, should be simple enough
not to require detailed instructions, and should only take a
couple of minutes to complete.
The Group discussed various alternatives with respect to
the selection of dimensions, including a survey of patients
and the general population, to identify common dimensions
of relevance to all groups. Since the selection of dimen-
sions from such an exercise would still involve value
judgments, the Group members decided instead to draw on
their own expertise by undertaking a detailed review of
other available generic health measures. Contrary to
expectations, the dimensions suggested for inclusion as a
result of this exercise were broadly similar, differing more
on dimension nomenclature than on content. General
agreement settled on the following: mobility, daily activi-
ties and self-care, psychological functioning, social and
role performance, and pain or other health problems [4]. In
addition, as the Group was multilingual, the classification
system descriptors were selected from the outset with a
number of languages in mind, rather than a source version
being translated into other languages.
The EuroQol Group publicly introduced a six-dimen-
sional health status instrument after some 3 years of devel-
opment [1]. However, by the time of its publication, further
empirical testing had already led the instrument to be further
refined to five dimensions—mobility, self-care, usual
activities, pain/discomfort and anxiety/depression—each
with three levels. Originally named the ‘EuroQol instru-
ment,’ it was formally designated ‘EQ-5D’ in 1995. The
descriptive system defined (35) = 243 different states. Two
further states were initially included in valuation work:
unconscious and dead (both states undefinable in terms of the
descriptive system). With the development of the five-level
version EQ-5D-5L (see Sect. 2.4), the three-level version
was re-designated EQ-3D-3L. (Both versions appear as
Appendices 1–4 in the online Supplementary Material).
Initial EQ-5D valuation work employed ranking, mag-
nitude estimation and visual analogue scale (VAS)
approaches, but VAS was quickly established to be the
valuation approach of choice. At that point in time, other
methods were in their infancy, such as time trade-off
(TTO), or had not been much applied in the health status
context, such as the standard gamble (SG). It was for that
reason that the EQ VAS was introduced as part of the EQ-
5D questionnaire right from the start: its initial role was
actually as a warm-up task for the VAS valuation tasks, and
only later was its potential usefulness as a self-reported
global measure of overall health recognised [5].
While these early efforts converged on a descriptive
system in what was a relatively short period of time, a
considerable and rapidly expanding research programme
continued, to test the reliability and validity of the EQ-5D
in populations and patients. This was accompanied by an
extensive programme of research on the valuation of EQ-
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5D, to test the effect on values of the stated duration of
states; the visual presentation and positioning on the VAS
scale; the selection of the states to be valued; and delib-
eration about whose values (experts, patients, or the gen-
eral public) should be used. It is important to note that
these efforts preceded—by over a decade—the establish-
ment of formal health technology assessment (HTA)
organisations and processes, so the EuroQol Group was
operating in largely uncharted territory.
2.2 Consolidation and Expansion
The two and a half decades which followed the establish-
ment of the EQ-5D in 1990 were characterised by contin-
ued research and development, considerable growth in the
use of the EQ-5D in healthcare decision-making, and
ongoing efforts to develop both additional instruments
within the EQ-5D framework and improved methodologies
for eliciting and modelling health state values. There were
also significant changes in the EuroQol Group as an
organisation—it grew, formalised its processes and put in
place the business model which exists today.
First, it is noteworthy that, apart from some minor
wording and design changes to the original EQ-5D ques-
tionnaire, what is now termed EQ-5D-3L has remained
more or less unchanged from 1990 to the present day.
While there has been ongoing experimentation with addi-
tional dimensions and the number of levels, as discussed
below, these changes have not been incorporated in the
EQ-5D-3L instrument itself.
This stability in the EQ-5D 3L instrument has had a
number of consequences. After two and a half decades of
use and research, there is a substantial back-catalogue of
studies, evidence and EQ-5D data available to support new
investigations. Research has built upon and developed
knowledge of the use and analysis of EQ-5D data. From the
perspective of its application in HTA, this stability can
facilitate consistent decisions over time.
Expansion in the use of EQ-5D post-1990 came in a
number of ways. First, the demand for EQ-5D data and the
accompanying value sets increased markedly as HTA
organisations became established in healthcare systems
around the world. Second, considerable resources were
devoted to expanding the number of EQ-5D language
versions, facilitating global use of the instrument. Third,
there was a rapid increase in the number of applications for
licences to use the EQ-5D in a variety of medical and
health sector settings, and pharmaceutical companies began
to use the instrument in increasing numbers, reflecting the
requirement of HTA bodies to supply evidence on QALYs.
In the valuation context a noteworthy development came
from the Measurement and Valuation of Health (MVH)
study, led from the University of York in the early 1990s,
in the form of a set of EQ-5D ‘tariffs’ based on TTO values
from the general public which could be used to generate
QALYs. The tariff (value set) produced from the MVH
study [6] became very widely applied in economic evalu-
ation, both in the UK and in other countries (and continues
to be used today). This subsequently led to a number of
other countries adopting similar methods for collecting and
modelling their own value sets.
Also of significance for the progress of the EuroQol
Group was the EQ-net project of 1998–2001 funded by the
Biomed programme of the European Commission. This
project provided the opportunity to put members’ research
work into a more structured context, with most of the
efforts of the Group devoted to it during this 3-year period.
The tasks involved were divided into three sub-projects:
Translation, Valuation and Application. In addition, the
communication of information and knowledge about EQ-
5D was addressed, with detail on all aspects of the project
subsequently being published in book form [7]. Since the
main aim of the project was to harmonise data on the
valuation of EQ-5D health states collected in different
European countries, considerable effort was put into the
Valuation sub-project. Two databases were established,
one containing VAS valuations and the other TTO valua-
tions. The Application sub-project produced standard
operating procedures (SOPs) for the design, analysis and
reporting of EQ-5D in clinical, economic and population
studies, which were included in the book alongside
guidelines for differing modes of administration of EQ-5D:
versions for observer, face-to-face administration, proxy
and telephone. The work accomplished in the Translation
sub-project is treated separately in Sect. 2.4 below.
Essentially the EQ-net project stimulated the further
development and dissemination of EQ-5D, which fed into
the scientific programmes pursued in the new millennium.
2.3 The Evolution of the EuroQol Group
as an Organisation
As use of the instrument grew, the relatively simple club-
like nature of the early Group necessarily evolved into
more formalised arrangements. The use of EQ-5D in HTA
(particularly by NICE in the UK, which, in 2004, identified
the EQ-5D as its preferred instrument [8]) led to increased
demand from pharmaceutical companies wanting to
include EQ-5D data in HTA submissions. This presented
an opportunity to license that use and to generate revenue.
A key period in the evolution of the Group in this respect
was 1993/94. Up until 1993, the activities of the Group
were supported exclusively by the initial small group of
members and their institutions, both by contributing their
time and, occasionally, by contributing financial support to
the enterprise.
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The next development was the appointment of a Busi-
ness Manager and a Management Assistant in 1993 and
1994, respectively. In 1994, inquiries from the pharma-
ceutical industry began to be directed through the business
office, which was instructed to develop a pricing policy.
This marked the beginning of modest revenue generation,
in keeping with the not-for-profit nature of the Group.
This was quickly followed by setting in place legal
arrangements. In 1995 the formal organisational (and legal)
structure for the Group comprising the EuroQol Associa-
tion and Foundation, monitored by a Board and Executive
Committee, were established under Dutch law, and a
Business Management office set up in Rotterdam.
Critical to understanding the current nature of the
EuroQol Group was the business model which emerged
from this process of formalising the organisation in the
mid-1990s. The key features are:
• The EuroQol Group in all its activities is a not-for-
profit organisation.
• Users must register use of the instrument (copyright to
which was first asserted in 1990 and was formally
transferred to the Association upon its establishment in
1995).
• Commercial, for-profit users are changed a licence fee
for the use of EQ-5D.
• Not-for-profit academic users are able to use EQ-5D
free of charge.
• The EuroQol Group comprises both a business unit and
an international, multi-disciplinary collaborative net-
work of researchers—the members of the EuroQol
Group—who drive forward the science surrounding the
EQ-5D.
This combination of arrangements proved an appropri-
ate model for promulgating the use of EQ-5D and gener-
ated revenue with which to support and fund research.
Group membership expanded—currently at around 80—
and has become an international rather than a European
network. In addition, with some members having a career-
long association with the Group there has been a great deal
of continuity of endeavour.
2.4 Instrument Development
In Sect. 2.2 we noted that the EQ-5D-3L as an instrument
has remained largely unchanged from 1990 until the pre-
sent. However, there have been important related devel-
opments, including many new language versions, newly
derived EuroQol Group instruments and systematic
approaches to valuation for use in producing value sets. We
briefly review the principal developments below, after
outlining translation and version management issues.
2.4.1 Translation and Version Management
From the outset English had been used as the working or
‘source’ language for the EQ-5D, and the instrument was
simultaneously constructed in Finnish, Dutch, Swedish and
Norwegian. Draft translation guidelines were first devel-
oped in 1994, and in 1996 expanded guidelines were
implemented, overseen by a Translations Committee, set-
ting in place a standard forwards-and-backwards transla-
tions process which supported the development of a large
number of language versions in subsequent years.
When EQ-5D spread to new languages the process of
translation pointed to difficulties in language usage and to
differences in the conceptualisation of EQ-5D dimensions
and items across countries and languages. This led the
Group to consider more closely the meanings of concepts
and the related wording used in EQ-5D, not least in Eng-
lish. The Translation aspect of the EQ-net project provided
the opportunity for substantive work on these matters. A
definition of EQ-5D concepts was provided and a series of
recommendations for further research was made [9]. Also
generated were a taxonomy of definitions of EQ-5D con-
cepts, SOPs and detailed translation guidelines. A detailed
account of translating EQ-5D into 11 European languages
provided an insight into the translation process, and the
challenges involved [10].
In 2009 a Version Management Group (subsequently
Committee) was established, with responsibilities for
reviewing new language versions, responding to client and
translation agency queries, updating essential documenta-
tion, and implementing systems aimed at improving ver-
sion control and management. This group has
responsibility not just for different language versions, but
also for testing and approving electronic versions of the
EQ-5D (tablet, web-based, PDAs), demand for which has
risen [11].
2.4.2 EQ-5D-5L
Notwithstanding the strong uptake in the use of EQ-5D,
particularly in HTA, concerns about its adequacy as a
measure of HRQoL have been voiced. There continued to
be lively debate within the EuroQol Group going back to
1994 [12] regarding the three-level structure of the
response options (no, some, extreme problems/unable to)
and whether this was associated with ceiling effects and a
lack of sensitivity to changes in health. Kind and Macran
fuelled that debate, reporting an investigation of a five-
level version of the core five dimensions [13]. In 2005,
sufficient momentum on this issue had built such that a
EuroQol Group task force was established to consider an
increased level descriptive system, in response to concerns
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about the perceived lack of sensitivity of the EQ-5D and
ceiling effects in the descriptive system.
In 2006, after considerable debate and pre-studies about
whether to go for a four- or five-level version, it was decided
to recommend the development of a five-level version of the
instrument, while retaining the same core five dimensions. In
addition ‘confined to bed’ was replaced by ‘unable to walk
about’ to increase sensitivity of the mobility dimension.
Results from initial studies testing five-level versions of the
EQ-5D showed increased reliability, sensitivity (discrimi-
natory power) and feasibility [14–17].
As with the original EQ-5D, the intention behind the new
five-level version was that it be accompanied by value sets.
For that reason, rather than assign the additional two levels as
‘unlabelled’ response options between no and some, and some
and extreme, problems, it was felt that all five levels required
labels. Labels were selected following the results of semantic
testing in England, Spain and France [18, 19], and the resulting
labels translated into other languages. Two features of this
process can be highlighted. First, the labels were chosen for
UK English, Spanish and French, based on an exhaustive
process of response scaling among a wide range of potential
labels selected from the literature and existing PRO ques-
tionnaires, together with follow-up focus group research to
explore respondents’ understanding of those labels in the three
countries. Second, once the labels had been decided on, the
UK English, Spanish and French versions could then be used
as source content for any new language versions required.
These are produced following the EuroQol Group’s transla-
tion methodology, which also includes in-depth semantic
testing of all wording in the target language, with a particular
focus on the severity labels (see [11]).
The new instrument was approved as an official Euro-
Qol instrument in 2009. From that point, the five-level
instrument has been referred to as the EQ-5D-5L, and the
original EQ-5D has been re-named the EQ-5D-3L. The
research underpinning the EQ-5D-5L is summarised in
Herdman et al. [20], including consideration of the map-
ping of health states from one system to the other.
2.4.3 EQ-5D-Y
The EQ-5D was, implicitly, designed for self-completion
by adults. However, HTA bodies and other healthcare
decision-makers frequently make decisions regarding
treatments for children and young people. From 1998,
interest grew in the possibility of using the EQ-5D, or
adapting it in some way, for use in younger people. An
initial ‘child friendly’ version of the EQ-5D, reported in
2002 [21], was followed by research efforts in a range of
countries. A task force, established in 2006, coordinated
these efforts, and considered issues regarding what
dimensions to include and how to label them, what number
of levels to use, proxy completion, what age ranges to
target, and how to value children’s health states [22, 23].
These efforts culminated, in 2009, in approval of a ‘youth’
version, the EQ-5D-Y, as an official EQ-5D product. The
EQ-5D-Y retained the same five-dimension, three-level
format of the EQ-5D, but dimensions were described in more
appropriate language as: mobility (walking about); looking
after myself; doing usual activities; having pain or discom-
fort; feeling worried, sad or unhappy. (EQ-5D-Y appears as
Appendix 5 in the online Supplementary Material).
EQ-5D-Y is suitable for self-completion by children
aged 8–11 years; it is also recommended for use at ages
12–15 years, although use of the EQ-5D adult version
might be possible in some circumstances. The EQ-5D adult
version is recommended for those aged 16 years and over.
2.4.4 Protocols for Value Sets
Despite the widespread utilisation of the MVH tariff for
QALY purposes there was no ‘official’ valuation protocol
or consensus view within the EuroQol Group about valu-
ation methods to be used in producing value sets. Different
research teams adapted the MVH study design in various
ways, making different choices about, for example, the
number and selection of states to value; ‘exclusion rules’
applied to the data; and so on [24]. This limited the com-
parability of the data. This was addressed in 2009 at a
meeting in Paris, where a modified version of the MVH
study design was endorsed (‘the Paris protocol’) for use in
EQ-5D-3L value set studies. Included among the changes
incorporated at that point was dropping ‘unconscious’ from
the states to be valued in such studies.
Having developed the EQ-5D-5L, the EuroQol Group
decided this presented an important opportunity to improve
valuation methods and to promote a consistent approach to
valuing EQ-5D-5L by providing an official protocol and
study design. Interim values for the EQ-5D-5L were
available from a ‘crosswalk’ study: six countries adminis-
tered both the five-level and three-level versions in parallel,
from which a crosswalk enabled EQ-5D-5L profiles to be
mapped to EQ-5D-3L profiles, and values applied from
existing EQ-5D-3L value sets [25]. At the same time, a
series of methodological studies were undertaken, explor-
ing a variety of approaches to both TTO and discrete
choice experiments (DCE). The latter method had been
investigated in 2008 using the three-level version [26].
Work was also undertaken to develop thesoftware to allow
these methods to be implemented in computer-assisted
personal interviews (CAPI). A prototype protocol, incor-
porating these approaches, was piloted in a multi-country
study [27].
Following further testing and refinement, the interna-
tional protocol for valuation of EQ-5D-5L was launched
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[28]. This comprises a fully documented study design,
interviewer guide, interviewer training materials and the
CAPI software, EQ-VT (EuroQol Valuation Technology).
Valuation studies in England, The Netherlands, Spain and
Canada commenced in 2012, coordinated and supported by
the EuroQol Executive Office.
3 EQ-5D: The Current State of Play
The EuroQol Group operates within a formal legal and
organisational framework, and undertakes formal processes
for decision-making to ensure accountability and trans-
parency. The Executive Office in Rotterdam administers
licensing arrangements, manages Group operations, pro-
vides scientific advice and undertakes research, and acts to
support and coordinate the activities of all its members.
Its stated vision is:
‘‘To improve decisions about health and health care
throughout the world by developing, promoting and
supporting the use of instruments with the widest
possible applicability for the measurement and valu-
ation of health’’ [29].
Its stated mission [30] is: (1) to provide leadership in the
research and development of instruments that describe and
value health. (2) To promote the use of instruments
developed by the EuroQol Group and to support individ-
uals and organizations across the world seeking to use
those instruments. (3) To foster and support an interna-
tional community of researchers whose activity informs the
development and application of EuroQol Group instru-
ments. (4) To ensure access to the accumulated research
expertise of the EuroQol Group and to actively promote the
transfer of knowledge and evidence regarding the use,
analysis and interpretation of measures developed by the
EuroQol Group. (5) To support early career researchers in
the field of health and quality-of-life research through
involvement in EuroQol Group activities.
3.1 Availability and Use of EQ-5D Instruments
The position in 2016 with respect to translations, as
detailed on the EuroQol website (http://www.euroqol.org),
is 176 EQ-5D-3L and 138 EQ-5D-5L language versions. In
addition alternative available formats comprise: proxy,
telephone interview, IVR (interactive voice response) via
telephone, web, tablet and PDA.
The number of studies using the EQ-5D suite of instru-
ments, registered with the EuroQol Group, totalled over
17,000 by 2015. These comprised over 80 clinical areas and
40 programmes and settings. For studies in the top 25 clinical
areas, apportioned by type of study, the figures were: inter-
ventional studies (including randomised control trials) 33%,
observational studies 28%, surveys 15% and other studies
24%. Programmes and settings included, inter alia, surgical
procedures, general practice and primary care, hospital
waiting lists, physiotherapy and rehabilitation.
Further information is shown in Tables 1 and 2.
3.2 New and Emerging Uses of EQ-5D
EQ-5D instruments continue to be used to measure the health
status of patients, and to provide evidence on the cost-ef-
fectiveness of healthcare technologies, and in population
health surveys to examine the health of the general public.
More recently, there has also been growing use of the
EQ-5D as part of routine, administrative data collection in
Table 1 The EuroQol Group’s current suite of instruments
EQ-5D-3L EQ-5D-5L EQ-5D-Y
Number of language (paper) versions available 176 138 40
Number of new requests to use the instrument in 2015 1416 2274 34
Number of value sets available (?planned) 25 22 None: pilot projects currently underway
Number of observations collected in 2015 [1.3 million [2.9 million 5600
Source: EuroQol Executive Office
Table 2 Availability and use of EuroQol Group Valuation Technology (EQ-VT)
EQ-VT
Number of translated versions available 22
Value sets available or planned using
EQ-VT n = 16
Value sets available: Argentina, Canada, China, England, Hong Kong, Japan, Netherlands, Spain
Value sets currently underway/planned: Germany, Indonesia, Ireland, Norway, Singapore, South
Korea, Thailand, UK
Source: EuroQol Executive Office
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healthcare systems. In 2009, NHS England introduced its
Patient Reported Outcome Measures (PROMs) pro-
gramme: the EQ-5D, alongside condition-specific PROs, is
collected from all NHS patients before and after elective
surgery for hip and knee replacement, varicose veins and
hernia repair [31]. These data are used to monitor the
performance of healthcare providers, to incentivise quality
by linking reimbursement to performance, and to inform
patient choice of provider. Similar uses of EQ-5D are
underway, or planned, in the healthcare system in Sweden,
and in Alberta Health Services in Canada. The private
healthcare sector also uses EQ-5D—for example, Southern
Cross, New Zealand’s largest private insurance company,
require providers to collect these data as a means of
checking the quality of care they fund. These PROMs
programmes generate large-scale data—they cover entire
populations, rather than samples, of patients, and are gen-
erating powerful real-world insights on treatment and
provider effectiveness, beyond the confines of clinical tri-
als. EQ-5D has thus become part of the ‘big data’ revolu-
tion in health care [32]. This emerging use poses new
challenges for issues such as data sharing and methods to
achieve comparability of responses.
4 The Future of EQ-5D
The future of the EQ-5D instruments will depend both on
internal factors—the aims and scientific strategy of the
Group—as well as on changes in the external environment,
for example, developments in HTA, and new and emerging
uses of EQ-5D outside HTA.
4.1 The Scientific Strategy of the EuroQol Group
In 2014 the EuroQol Group initiated a process to define its
scientific strategy. The outcome included a revised and
augmented system of six working groups. Each is tasked to
drive forward research in a key area. This framework indi-
cates the priorities of the EuroQol Group, and where future
developments will take place as a result of these efforts.
Table 3 lists these groups, and their major objectives.
Table 3 EuroQol working groups and their main objectives
Descriptive systems
To explore the conceptual basis for generic preference-based HRQL measures (i.e., descriptive and measurement work)
To investigate the conceptual basis and develop a framework to rationalize the development of various bolt-ons and bolt-offs
Valuation
To investigate new approaches to valuing health (including approaches within scope of the QALY framework)
To support the development and dissemination of EQ-5D-5L value sets in key countries and stimulate interest in producing EQ-5D (3L and
5L) value sets in key countries
To support methodological research examining the basis/rationale for value sets for patient groups
To provide scientific guidance and support for existing protocols related to valuation studies
To provide scientific guidance and support for valuation of bolt-on studies
Large-scale applications
To promote and examine large-scale health systems applications for EQ products
To stimulate methodological and applied research relating to the use of EQ-5D in measuring local and system-wide performance, as well as
its use in assessing population health
To focus on applications inside healthcare systems, as well as in other non-health sectors
EQ-5D in younger populations
To develop EQ-5D instruments suitable for use in younger populations of various age ranges
To promote research to explore the validity of the EQ-5D-Y as a measure of health status in younger populations
To work closely with the Working Group on Valuation in developing a work programme for the valuation of EQ-5D-Y states
To promote research in the field of application studies
To develop and to test possible bolt-ons and bolt-offs (with regard to the self-care dimension) for the EQ-5D-Y
Interface development
To support different end-users of the EQ-5D instruments who wish to use electronic or internet-based methods of data collection
Education and outreach
Organize regular educational meetings for interested EuroQol members on specific topics related to research and application of EQ-5D
Organize and promote regional meetings of researchers, decision-makers and users interested in EQ-5D outside Europe and North America
Propose educational and uptake initiatives that could be supported by the EuroQol Foundation
Source: EuroQol Executive Office
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One aspect of these priorities is the intention to revisit
the descriptive system. Systematic reviews of the use of
EQ-5D indicate its acceptability as a measure of health
status in most disease areas [33], although there are some
types of health problems where the EQ-5D appears not to
perform well, such as problems with hearing and vision.
Nevertheless, there have been considerable advances in
health status measurement and the science of PRO instru-
ment development since the initial development of EQ-5D
in the late 1980s, hence the Group considered that it would
be appropriate at this juncture to explore whether the
instrument could be improved and its performance
enhanced and, if so, in what ways. The Group has therefore
signalled its intention to undertake a ‘fundamental’
research programme to address the conceptual and empir-
ical basis for the core instrument, as indicated in Table 3. If
evidence provides clear support for making changes to the
conceptual model or to instrument content, this will lead to
discussion around whether a new version of the instrument
should be developed and the methods for doing so. This
would clearly be a long-term research endeavour and an
important part of the discussion would be the implications
of making any significant changes.
The Group is also undertaking experiments on another
approach to enhancing instrument performance in certain
population sub-groups, i.e. through the use of ‘bolt-on’
dimensions. In its simplest form, this retains the core five
dimensions, but adds one (or more) dimension to capture
aspects of health which may not adequately captured by
these dimensions. Some initial experiments with bolt-ons
have been undertaken for vision, hearing, tiredness, psori-
asis and sleep [34–36]. At a descriptive level, the intro-
duction of bolt-on dimensions can add to the richness of
respondent profile data. However, this approach raises non-
trivial issues, especially in connection with the conse-
quences for health state valuations in the expanded
instruments [33, 36].
4.2 Changes in the External Environment Affecting
the Demand for EQ-5D
The future of the EQ-5D is closely linked to developments
in healthcare systems with respect to measuring outcomes,
and how outcomes data are used by decision-makers. EQ-
5D has been a cornerstone of QALY-based HTA systems
and its continued use in that context depends on the extent
to which QALYs and cost-effectiveness analysis remain an
integral part of HTA. Critiques of QALYs have long
existed and continue to generate debate. In recent years,
there has been growing interest in the inclusion of other
elements of value that might be missed by QALYs, such as,
inter alia, patients’ preferences regarding their treatment,
benefits to caregivers and social benefits from increased
productivity. It has also been suggested that there needs to
be a shift to new measurement paradigms—such as
assessing treatment benefits in terms of gains or losses in
subjective wellbeing. If such suggestions gain traction EQ-
5D may become less important in this context [37–40].
Notwithstanding the growing interest in going ‘beyond
QALYs’, it seems likely that the QALY will remain a
central part of HTA for some time to come—in part
because of the challenges in implementing a radically
different approach and the difficulty in making such a
fundamental change, and in part because of the lack of any
other credible measurement approach to ‘value’ which
could replace it.
Furthermore, HTA systems are being established in ever
more parts of the world—South America, Africa, Asia—so
demand for EQ-5D instruments seems likely to continue to
grow as these areas of the world require local evidence to
inform their decisions.
EQ-5D usage expanded because the instrument provided
a simple and effective means to compare the impact of
disease and its treatment across different disease areas and
patient groups, and of incorporating societal preferences
for health states into those comparisons. A further factor
which may affect future demand for EQ-5D is the rise of
condition-specific instruments accompanied by utilities:
this means that utility becomes the common denominator
for comparison of QALYs (providing utilities are generated
using consistent methods, and give commensurate mea-
sures of utility), not the generic health state descriptive
system itself.
Finally, demand for EQ-5D will also be affected by its
growing use outside of HTA, to inform different kinds of
decisions. This includes the potential for EQ-5D to have a
role in clinical settings, as part of patient decision aids [41]
and the growing inclusion of EQ-5D in routine, adminis-
trative data in healthcare delivery, as reported in Sect. 3.2.
These new uses of EQ-5D may have implications for the
future development of methodologies to support its use.
For example, where EQ-5D is used to monitor the perfor-
mance of providers, appropriate case-mix adjustment
methods become crucial, as does an understanding of how
much variation in performance is ‘normal’. Given the large
scale of health system-wide data collection of EQ-5D data
in PROMs programmes, a better understanding of what
constitutes a minimally important difference in EQ-5D
arguably also becomes more important.
Further, these uses of EQ-5D serve quite different types
of healthcare decisions and decision-makers (e.g. patients’
decisions about what treatments to choose, regulators’
monitoring of quality standards of healthcare providers)
than those that have conventionally been the focus of EQ-
5D (e.g. budget holders’ decisions about how resources are
allocated in the healthcare sector or HTA decisions about
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whether new technologies are good value for money). This
potentially has implications for the way EQ-5D profile data
are summarised: the use of ‘value sets’ reflecting the
preferences of the general public has a normative justifi-
cation specific to the use of those data in resource alloca-
tion decisions [42]. In contrast, judgements about what
constitutes ‘good quality health care’, or individual
patients’ choices between different treatments, might sug-
gest a role for patient preferences, rather than those of the
general public, in summarising and analysing EQ-5D data
[43]. These are areas for future exploration.
5 Discussion
Four major factors in the development over time of EQ-5D
can be discerned.
1. The determination from the outset that a generic health
status instrument should be as short and simple as
possible to minimise the burden of both measuring and
valuing health status led first to its adoption by medical
personnel, and then later supported and facilitated the
burgeoning interest in economic evaluation in health
care and the establishment of HTA by NICE and
similar bodies internationally. Associated with these
developments was the requirement laid on pharma-
ceutical companies to demonstrate the cost-effective-
ness of their products. Initially, and for several years,
the EuroQol Group maintained that its instrument was
to be used ‘alongside’ other instruments in evaluating
medical programmes, and indeed this has often been
the case. However, EQ-5D increasingly came to be
employed as a stand-alone instrument.
2. The ‘not for profit’ business model employed by the
Group generated a stream of revenue from commercial
users with which to fuel further research—while
simultaneously allowing free use of the instrument
by academics. This flow of funds has continued, and
indeed increased in volume and value, thus enabling
new and innovative research to be pursued by a Group
whose membership and geographical scope has
steadily expanded.
3. Another key aspect of the expansion in the utilisation
of EQ-5D, geographically and otherwise, has been the
‘open access’ policy pursued by the Group from the
outset. This included: publishing the proceedings of
Plenary meetings, which are all available in both book
form and on the EuroQol website; a commitment to
publishing research in peer-reviewed journals wher-
ever possible; and extended to an open access policy
for Group publications.
4. Notwithstanding considerable experimental research
over the last 25 years, the EQ-5D-3L instrument has
remained fundamentally unchanged from its establish-
ment in the early 1990s. New versions of the
instrument have thus far retained the same five
dimensions, but, in the case of EQ-5D-5L, expanded
the number of levels, and in the case of EQ-5D-Y,
adjusted the way dimensions are communicated. The
overall outcome of this is that the EQ-5D is backed by
over a quarter century of data, evidence, publications,
and researcher and user experience. This offers
considerable appeal to both researchers and decision-
makers: new data can be compared to EQ-5D popu-
lation norms, EQ-5D evidence from specific disease
groups, and so on.
There are, however, challenges in turning science into
‘products’. EQ-5D-3L was developed with the clear
intention of producing a generic instrument accompanied
by values. EQ-5D-5L and EQ-5D-Y had the same objec-
tives—but a notable difference in the development process
underpinning these new instruments is that piloting of the
valuation of health states has not fed into the instrument
development phase in either case, but tended to take place
after the instruments have been finalised. This has given
rise to some issues. For example, difficulties have arisen
for members of the general public in differentiating
between levels 2 and 3 and levels 4 and 5 when responding
to valuation tasks on the EQ-5D-5L.
A further potential issue emerging from the increased
scale of use of EQ-5D and the need to adopt a more
‘business-like’ approach to product development is the
challenge of balancing clients’ needs with the long time-
lines associated with academic methodological research.
There have been understandable reservations within the
Group about changing the descriptive system. The initial
descriptive system was not developed using the techniques
now available in modern psychometrics—and the Group
has now embarked upon a fundamental programme of
research to revisit the core descriptive system, as well as
exploring the potential conceptual and empirical basis for a
suite of bolt-on and bolt-off dimensions, as noted in Sect.
4.1. This research does not commit the Group to a ‘new’
EQ instrument—but it may ultimately lead in that direc-
tion. That decision point will be a critical one for the future
of the EQ-5D: improvements in the measurement system
may mean better science, but breaking away from the
current EQ-5D loses the appeal to current users of history
of evidence and consistency.
Notwithstanding continued objections to the use of
QALYs in HTA [44], most policy responses so far have
entailed more explicitly taking into account additional
aspects of ‘value’ (such as process-of-care utility, effects
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on workforce productivity, the reduction in health
inequalities) alongside the QALY (for example, the pro-
posal to establish ‘value based pricing’ in the UK [45]),
rather than a rejection of the QALY per se. Furthermore,
while formal, QALY-based HTA processes were initially
restricted to Europe, Canada, Australia and New Zealand,
similar HTA processes are now being established, or
actively planned, in Asian, African, Middle Eastern and
South American healthcare systems [46–48]. This is likely
to generate a new wave of demand for the EQ-5D.
In addition, new uses for the EQ-5D outside of clinical
trials and technology appraisal—most notably, the inclu-
sion of the EQ-5D in routine outcomes measurement in
healthcare systems (i.e. PROMs programmes)—have quite
considerably increased the amount of data being collected
and used. A key challenge for the future will be to
recognise that these new uses of the EQ-5D, which are not
principally driven by cost-effectiveness, QALYs or
resource allocation, address quite different questions—and
that this is reflected in the development of appropriate
methods and research to support these applications, as we
detailed in Sect. 4.1.
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